Weather The Fed With AbbVie’s Strong Portfolio And Solid Dividend Growth

Summary:

  • AbbVie’s Humira sales may hold up better against biosimilars in the USA than they have in Europe.
  • The pharmaceutical giant has a diverse portfolio of blockbuster drugs that should help to offset declining revenues in its leading therapies.
  • AbbVie offers a safely growing dividend with a current yield near 4%.
  • I examine AbbVie’s current outlook, dividend strength, and valuation to determine whether ABBV stock is a buy at current levels.

Cancer cells on dna stand background. 3d illustration

Mohammed Haneefa Nizamudeen

Amidst the current market turmoil largely driven by the Fed’s rapid rate hike campaign and its potential near-term ramifications across the financial sector, many investors are seeking safer places for their capital, both in equities and fixed income, to

ABBV Historical Dividends

ABBV Historical Dividends (dividendinvestor.com)

ABBV Payout Ratio 2013-22

ABBV Payout Ratio 2013-22 (Seeking Alpha)

ABBV Valuation

ABBV Valuation (Morningstar)

ABBV Valuation

ABBV Valuation (Seeking Alpha)

ABBV 2023 EPS Projections

ABBV 2023 EPS Projections (Seeking Alpha)


Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.


Leave a Reply

Your email address will not be published. Required fields are marked *